Curcumin-LPPC-Herceptin and doxorubicin-LPPC-Herceptin complexes dramatically enhanced the cytotoxic effects of LPPC-encapsulated curcumin on HER2-positive cells, with a potent therapeutic effect on SKBR3 (HER2 positive) as compared to Hs578T (HER2 negative) breast cancer cells[216]. Here, ERBB2 is linked to breast cancer.